The Food and Drug Administration on Friday approved two gene therapies to treat sickle cell disease, one of the which is the first CRISPR/Cas9-based treatment to win regulatory approval in the US. The ...
In the ever-evolving realm of modern medicine, a once-distant dream to conquer disease through genetics has now inched closer to reality. Last Friday, the U.S. Food and Drug Administration approved ...
Doudna lab finds chromosome loss from CRISPR-Cas9 is common—and swapping steps is key to stopping it
When it comes to solving math problems, the order of operations matters (PEMDAS, from left to right!). That appears to be the case for engineering T cells with CRISPR-Cas9, too, as new research from ...
Nobel Prize winner and CRISPR DNA-editing pioneer Jennifer A. Doudna, PhD, spoke Thursday at Fred Hutch Cancer Center in Seattle. Her lecture kicked off the President’s Seminar series, presented by ...
Sickle-cell disease is the first illness to be beaten by CRISPR, but the new treatment comes with an expected price tag of $2 to $3 million. CRISPR Therapeutics, Editas Medicine, Precision BioSciences ...
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly ...
The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
6don MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
Researchers have now used a gene-drive system to suppress an important agricultural pest. Researchers have developed a "homing gene drive system" based on CRISPR/Cas9 that could be used to suppress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback